Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$15.24 +2.8%	$10.89	$6.38 ▼ $16.66	$1.48B	1.47	1.20 million shs	1.55 million shs
BNTC Benitec Biopharma	$12.99 +2.3%	$12.58	$8.06 ▼ $17.15	$340.99M	0.4	42,222 shs	74,167 shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CVAC CureVac	$5.44 +0.4%	$5.44	$2.37 ▼ $5.72	$1.22B	2.53	704,959 shs	353,942 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	+2.83%	+11.32%	+37.67%	+66.92%	-6.39%
BNTC Benitec Biopharma	+2.28%	-0.15%	+9.62%	-1.52%	+44.98%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	-1.33%
CVAC CureVac	+0.37%	-0.73%	-0.37%	+33.01%	+63.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	2.7013 of 5 stars	3.6	3.0	0.0	0.0	2.0	1.7	0.6
BNTC Benitec Biopharma	1.3457 of 5 stars	3.6	1.0	0.0	0.0	1.3	0.8	0.0
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	4.6442 of 5 stars	4.1	5.0	0.0	4.9	1.6	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.14	Buy	$19.67	29.05% Upside
BNTC Benitec Biopharma	3.13	Buy	$26.00	100.15% Upside
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
CVAC CureVac	2.20	Hold	$6.83	25.61% Upside

Current Analyst Ratings Breakdown

Latest BNTC, AVDL, CVAC, and CALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	AVDL Avadel Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $20.00
8/8/2025	AVDL Avadel Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	AVDL Avadel Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $24.00
7/18/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$22.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/26/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral	$12.00 ➝ $5.50
6/13/2025	CVAC CureVac	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$7.00 ➝ $5.00
6/12/2025	CVAC CureVac	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
6/12/2025	CVAC CureVac	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/28/2025	CVAC CureVac	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$10.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	8.75	N/A	N/A	$0.93 per share	16.39
BNTC Benitec Biopharma	$80K	4,262.34	N/A	N/A	$4.68 per share	2.78
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CVAC CureVac	$579.18M	2.11	$0.87 per share	6.23	$2.97 per share	1.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.03	N/A	254.00	N/A	-1.32%	-3.73%	-1.73%	11/11/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CVAC CureVac	$175.50M	$0.96	5.67	N/A	N/A	38.21%	29.57%	25.41%	11/11/2025 (Estimated)

Latest BNTC, AVDL, CVAC, and CALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/21/2025	Q2 2025	CVAC CureVac	-$0.15	-$0.30	-$0.15	-$0.30	$4.27 million	$1.41 million
8/7/2025	Q2 2025	AVDL Avadel Pharmaceuticals	$0.02	$0.10	+$0.08	$0.10	$60.28 million	$68.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.79	2.38
BNTC Benitec Biopharma	0.01	14.80	14.80
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CVAC CureVac	0.05	6.17	7.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
BNTC Benitec Biopharma	52.19%
CALT Calliditas Therapeutics AB (publ)	2.83%
CVAC CureVac	17.26%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	5.20%
BNTC Benitec Biopharma	1.30%
CALT Calliditas Therapeutics AB (publ)	2.20%
CVAC CureVac	2.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	97.10 million	92.05 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
CVAC CureVac	880	224.34 million	219.52 million	Optionable

BNTC, AVDL, CVAC, and CALT Headlines

Recent News About These Companies

CureVac (NASDAQ:CVAC) Posts Earnings Results, Misses Expectations By $0.15 EPS

August 23 at 8:23 AM | marketbeat.com

Short Interest in CureVac N.V. (NASDAQ:CVAC) Decreases By 30.0%

August 22 at 8:40 AM | marketbeat.com

CureVac sees cash runway into 2028

August 16, 2025 | msn.com

CureVac reports Q2 revenue EUR 1.2M vs. EUR 14.4M last year

August 16, 2025 | msn.com

CureVac Reports Financial Losses in Mid-2025

August 16, 2025 | msn.com

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

August 15, 2025 | accessnewswire.comA

CureVac (CVAC) to Release Earnings on Thursday

August 15, 2025 | marketbeat.com

Companies roundup: GSK, Flutter and Assura

August 9, 2025 | investorschronicle.co.uk

GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute

August 8, 2025 | proactiveinvestors.co.uk

CureVac settles patent dispute litigation with Pfizer and BioNTech

August 7, 2025 | reuters.com

U.S. to phase out funding for mRNA vaccine development

August 6, 2025 | msn.com

GSA Capital Partners LLP Invests $853,000 in CureVac N.V. (NASDAQ:CVAC)

August 3, 2025 | marketbeat.com

CVAC - CureVac NV Ordinary Shares Key Metrics - Morningstar

July 9, 2025 | morningstar.comM

CureVac N.V. (CVAC) Has Gained Over 16% In One Month. Here Is Why

July 9, 2025 | insidermonkey.com

UBS Downgrades CureVac N.V. (CVAC)

June 27, 2025 | msn.com

CureVac Announces Voting Results of General Meeting

June 24, 2025 | accessnewswire.comA

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

June 20, 2025 | zacks.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)

June 20, 2025 | globenewswire.com

BioNTech SE Announces Acquisition of CureVac N.V.

June 17, 2025 | tipranks.com

M&A News: BioNTech Snaps Up CureVac in $1.25B Deal to Supercharge Cancer Pipeline

June 14, 2025 | theglobeandmail.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders

June 13, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC, AVDL, CVAC, and CALT Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$15.24 +0.42 (+2.83%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.26 +0.02 (+0.12%)

As of 08/22/2025 07:57 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Benitec Biopharma NASDAQ:BNTC

$12.99 +0.29 (+2.28%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.98 -0.01 (-0.08%)

As of 08/22/2025 04:04 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 08/22/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

CureVac NASDAQ:CVAC

$5.44 +0.02 (+0.37%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.43 -0.01 (-0.18%)

As of 08/22/2025 05:32 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time